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This article covers current research on the relationship between depression and cognitive 
impairment in older adults. First, it approaches the clinical assessment of late-life depression and 
comorbid cognitive impairment. Cognitive risk factors for suicide are discussed. Research is then 
provided on neuropsychological changes associated with depression, discussing subjective cognitive 
impairment, mild cognitive impairment, and dementia profiles. Additionally, literature regarding 
neuroimaging and biomarker findings in depressed older adults is presented. Finally, therapeutic 
models for treatment of late-life depression are also discussed, including psychotherapy models, 
holistic treatments, pharmacologic approaches, and brain-stimulation therapies. 
Keywords: Major depressive disorder; Subjective cognitive impairment; Mild cognitive impairment; 
Neurocognitive disorder; Neuropsychological testing; Neuroimaging; Psychotherapy; Antidepressants 
KEY POINTS 
• The assessment of late-life depression with comorbid cognitive impairment can be
challenging and requires a clear clinical history and a thorough medical and cognitive
assessment.
• There are several neuropsychological changes associated with late-life depression,
ranging from subjective cognitive complaints to mild cognitive impairment to dementia.
• Changes on neuroimaging and in several biomarkers (eg, apolipoprotein E e4 allele, beta-
amyloid, tau, neurotrophins, and so forth) have been associated with late-life depression.
• Multiple psychotherapeutic techniques have been found effective in the treatment of late-
life depression as well as holistic/nontraditional, pharmacologic, and brain-stimulation
approaches.
____________________________________________________
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INTRODUCTION 
Late-life depression affects 3.0% to 4.5% adults older than 65 years in the United States.1 For 
many older adults with depression, affective symptoms are accompanied by cognitive difficulties, 
which can range from subjective cognitive complaints to mild cognitive impairment (MCI) to 
dementia. Epidemiologic findings suggest that late-life depression may be a risk factor for 
dementia.2,3 Given the relatively high prevalence of depression in older adults and a growing 
focus on modifiable risk factors for dementia, there is interest in better understanding the 
complex relationship between depression and cognitive impairment. This review focuses on 
individuals with unipolar depression without psychotic features with comorbid MCI or dementia. 
To align with the terminology used in earlier literature and within the International Classification 
of Diseases, Tenth Revision coding system, the authors use Diagnostic and Statistical Manual of 
Mental Disorder (Fourth Edition, Text Revision) (DSM-IV TR) terminology (ie, MCI and 
dementia) instead of the DSM-5 terminology for neurocognitive disorders. 
Clinical Assessment of Late-Life Depression with Comorbid 
Cognitive Impairment 
Accurately diagnosing late-life depression can be challenging because of the wide variety of 
symptom presentations.4 A few key points can guide the clinical evaluation of depression in older 
adults with comorbid cognitive impairment. Specifically, these are (1) receiving a detailed history 
from both the patients and their informants, (2) following patients longitudinally to monitor 
symptom progression, and (3) interviewing with potential reversible causes of cognitive 
impairment in mind (eg, substance use, metabolic problems, and so forth). 
First, the most powerful diagnostic tool the clinician has is the clinical interview. Obtaining a 
detailed history from both the patients and their informants will be a critical piece to determine 
whether the patients have a primary mood and/or cognitive disorder. In certain cases, a detailed 
neuropsychological evaluation may be necessary to delineate cognitive and mood symptoms. 
Furthermore, neuropsychological testing is indicated when there are questions of multiple 
comorbidities, questionable self- or informant-report, and to establish a baseline in mild dementia 
and MCI cases. An accurate informant can be especially helpful, as many patients frequently 
experience anosognosia (lack of awareness due to neurologic disease) about their cognitive 
deficits or alexithymia (inability to describe one’s feelings). Patients may also experience 
variations in their mood depending on the time of day (ie, diurnal variations); therefore, an 
informant may be helpful in mapping the overall mood. 
Second, clinicians can follow patients’ symptoms over time. This technique can be important 
in the diagnosis of more complex cases when it is difficult to determine whether patients’ have 
primary cognitive disorder, primary mood disorder, or both. Clinicians should determine whether 
emotional and cognitive symptoms resolve, remain static, or progress over time. For example, if 
the cognitive symptoms worsen despite stable or improved mood, this would suggest a primary 
cognitive disorder. Alternatively, if the cognitive symptoms vary with emotional state, for 
example, worsening with increased emotional distress, this would suggest a primary mood 
disorder. 
When patients present with both significant emotional and cognitive complaints, 
clinicians should aggressively treat the depressive symptoms first and then reassess cognitive 
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symptoms after some resolution of the severe emotional distress. Literature has indicated that 
mild to moderate depression is best treated with a combination of antidepressants and 
psychotherapy.5 However, the patients’ cognitive capacity to engage in psychotherapy should 
always be considered. Electroconvulsive therapy (ECT) and other brain-stimulation therapies are 
generally reserved for severe or treatment-resistant cases. 
Third, clinicians should always approach these complex cases considering potential reversible 
causes of the patients’ mood and cognitive symptoms. One of the most overlooked, but easily 
reversible, causes of cognitive impairment in older adults is medication side effects. Specifically, 
research has shown that benzodiazepines, anticholinergics, opiates, non-narcotic pain medications 
(ie, tramadol), hypnotics, and antipsychotics have been associated with cognitive symptoms.6 
Substance use in older adults is frequently not explored thoroughly, particularly in regard to 
alcohol and cannabis use.7 Finally, a thorough workup for late-life depression should also include 
a comprehensive laboratory workup, assessing hematologic, metabolic, toxic, and infectious 
contributions to cognitive and/or affective symptoms. 
Risk Factors 
The interactions between medical illnesses, depression, and cognitive impairments are 
typically multidirectional, making it difficult to distinguish causes of current symptom 
presentations. Men, Caucasians, and individuals with functional impairments were more likely to 
present with affective symptoms of depression in MCI and early Alzheimer disease (AD).8 
Cerebrovascular disease has been associated with both late-life depression and comorbid 
executive dysfunction.9,10 Cognition and mood can also be impacted by other causes of organ 
failure, including chronic renal failure11,12 and chronic obstructive pulmonary disease.13,14 
SUICIDE AND COGNITION 
The incidence of suicide among individuals aged 85 years and older in the United States is 
17.8 deaths per 100,000 (compared with 15.0 deaths per 100,000 for those aged 65–84 years).15 
Although aging alone may increase the suicide risk, further research is needed to clarify the 
relationship between cognitive changes from aging and suicidality. The ventromedial prefrontal 
cortices, which are important in reasoning and decision-making, may become impaired in later 
adulthood16 and consequently increase the risk for suicidality. This impairment may be further 
exacerbated by changes in social support, that is, depressed elders with suicide attempts tend to 
have greater difficulties socially.17 Finally, many medical illnesses affecting older adults are often 
accompanied by comorbid depression and cognitive impairments, likely predisposing the affected 
older adult to suicidality.11,18,19 
NEUROPSYCHOLOGICAL CHANGES IN DEPRESSION 
Cognitive Aging 
Cognitive aging is characterized by gradual changes in cognitive functioning associated with 
normal aging.20 These changes can be variable between patients, are not secondary to a 
neurodegenerative illness or typically accompanied by functional decline, and generally 
accelerate in late life. Specific cognitive changes associated with aging include trouble with 
memory recall and executive dysfunction and slowed processing speed. In contrast, visuospatial 
skills, crystallized intelligence, and vocabulary knowledge remain stable.21 Generally, good 
management of multiple health factors, including hypertension, diabetes, chronic obstructive 
pulmonary disease, and so forth, and psychiatric disorders (including depression and anxiety) can 
help mitigate some of the changes associated with normal aging. 
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Subjective Cognitive Impairment and Depression 
Subjective cognitive impairment (SCI) refers to the perception of cognitive decline without 
evidence of deficits on objective measures.22 Several cross-sectional studies on the relationship 
between subjective cognitive complaints and objective impairments on cognitive testing have 
shown conflicting findings, ranging from a positive correlation23–25 to no association.26 However, 
in longitudinal studies, subjective cognitive impairments have been associated with higher rates 
of incident cognitive impairment and dementia.22,27–29 Of note, multiple studies have shown that 
subjective cognitive impairments are common in individuals with late-life depression, with ranges 
falling from 50% to 70%.30,31 Interestingly, one prospective study showed that tau-mediated 
degeneration, but not beta-amyloid (Aβ) deposition, was significantly higher in patients with MCI 
compared with SCI.32 At this time, although there seems to be compelling evidence of a 
relationship between SCI and depression, further research is needed to more fully understand the 
causal relationship between the two. 
Mild Cognitive Impairment and Depression 
MCI is characterized by cognitive complaints (per the patients, informants, or observed by a 
clinician), objective evidence of impairment, independence in functional abilities, and no 
impairment in social or occupational functioning.33 The prevalence of depression in MCI varies 
widely, with population-based estimates ranging from 3.0% to 83.0%, with a median prevalence 
of 44.3%; alternatively, the prevalence of MCI in depression ranges from 30% to 50%.34–36 For 
most individuals with late-life depression and comorbid cognitive impairment, the profile seems 
to be a dys-executive pattern37 characterized by difficulties with working memory, set-shifting, 
planning, and response inhibition. This syndrome suggests that cerebrovascular disease affects 
white matter tracts in the fronto-striatal pathways, resulting in executive dysfunction and, 
potentially, the affective symptoms of depression. Additionally, studies have found that late-life 
depression is associated with a higher ischemic burden on structural MRI as well as impaired 
executive and memory functions.38,39 
Dementia and Depression 
Longitudinal studies have provided information on the cognitive trajectories of those with 
late-life depression. Potter and colleagues40 found that baseline impairments in encoding and 
executive functioning in patients with depression seem to be risk factors for progression to 
dementia. However, this progression seems to be highly variable. Steffens and colleagues41 found 
that in a large group of nondemented depressed older adults, at the 2-year follow-up 
approximately 25% had reverted back to normal cognitive functioning, 15% had progressed to 
dementia, and the remainder continued to display cognitive impairments without functional 
decline. Additional research has shown that although one would expect most individuals with 
late-life depression and MCI to progress to a vascular dementia, these vascular risk factors may 
simply serve to accelerate the AD process.34,42 
BIOMARKERS 
Apolipoprotein E, Beta-Amyloid, and Tau 
Studies on various markers in neurodegenerative illnesses (ie, apolipoprotein E ε4 variant 
[APOE ε4], Aβ, and tau) and late-life depression have been variable. Regarding APOE ε4, there 
seems to be a significant relationship between depressive symptoms and APOE ε4 in regard to 
progression from MCI to dementia. Specifically, a longitudinal study showed that APOE ε4 
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carriers with depression were 4.4 times more likely to progress to AD compared with non-APOE 
ε4 carriers with depression.43 Meanwhile, a cross-sectional study found no relationship between 
APOE ε4 status, depression, and cognition.44 Further research on the relation between Aβ and 
APOE ε4 is mixed.45–48 Finally, although the relationship between tau protein and late-life 
depression has not yet been clearly established, a longitudinal study indicated those with late-life 
depression and elevated cerebrospinal fluid total tau levels progressed differently from MCI to 
AD.49,50 
Neurotrophins 
Recent literature has indicated that individuals with late-life depression display a reduction of 
neurotrophins, including nerve growth factor, glial-derived neurotrophic factor, and brain-derived 
neurotrophic factor.51–53 However, Arnold and colleagues54 found that 2 neurotrophins 
specifically associated with neurogenesis, long-term potentiation, and response to ischemic 
injuries seemed to be increased in older adults with depressive symptoms: vascular endothelial 
growth factor and hepatocyte growth factor (reflecting possible compensatory responses). 
Hippocampal-Pituitary-Adrenal Axis, Insulin Pathway, and 
Inflammation 
There is limited evidence suggesting that the hippocampal-pituitary-adrenal (HPA) axis and 
inflammation play a role in late-life depression with comorbid cognitive deficits. Although 
chronic distress has been associated with disruption in the HPA axis, research on this relationship 
with comorbid cognitive impairments has been variable.54,55 Interestingly, literature has provided 
compelling evidence of hippocampal atrophy in individuals with severe depression and positive 
inflammation biomarkers.56 
NEUROIMAGING AND ELECTROPHYSIOLOGY 
Structural MRI 
With structural MRI, changes in both white and gray matter have been associated with late-life 
depression and comorbid cognitive impairment compared with nondepressed older adults. In 
support of the vascular hypothesis, suggesting that cerebrovascular disease is a major contributor 
to late-life depression, longitudinal MRI studies have shown a correlation between the severity of 
depression and white matter ischemic changes.57,58 Similarly, these white matter lesions, 
especially when concentrated in anterior periventricular regions, have been associated with 
comorbid executive dysfunction. 
Gray matter changes seen in late-life depression may be part of the prodrome to AD. 
Hippocampal atrophy, a well-known feature of AD, has also been shown to be associated with a 
higher severity of emotional distress in nondemented individuals.59 For individuals with MCI, 
depression was associated with reduced thickness of the entorhinal cortex, anterior cingulate 
cortex, and bilateral dorsomedial and ventromedial prefrontal cortices.60–62 
Functional MRI 
The connectome (how the brain functions as a system of multiple connected networks) and 
how pathophysiologic processes can disrupt the connectome are now major areas of research. 
Recent functional MRI studies suggest that structural lesions associated with late-life depression 
can also lead to the disruption of networks associated with the clinical features in late-life 
depression (eg, apathy and executive dysfunction). In one study, the cognitive control network 
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and corticostriatal networks were shown to be linked to cognitive dysfunction (ie, executive 
impairments) in late-life depression.63 
PET Imaging and Florbetapir Imaging 
PET imaging studies provide conflicting information. Specifically, one study found that some 
patients with late-life depression and MCI showed a Pittsburgh compound B imaging pattern 
suggestive of AD,64 whereas another did not replicate this relationship.65 Research with an 
amyloid and neurofibrillary tangle binding agent (FDDNP) for individuals with MCI and 
depression found variable temporal and parietal lobe binding.66,67 This finding was further 
confirmed by research coming from the Alzheimer’s Disease Neuroimaging Initiative showing 
that lifelong depressive symptoms reliably predicted Aβ accumulation in patients with MCI.68 
These findings suggest that larger studies are needed to understand the complex PET imaging 
relationship between depression and cognitive impairment. 
Electrophysiology Markers 
Using electroencephalogram (EEG) technology, individuals with late-life depression have 
shown more slow-wave activity and prolonged P300a latencies, indicating decreased cerebral 
arousal and information processing.69 Additional researching using a complex response inhibition 
task showed decreased event potential localized to the anterior cingulate cortex in depressed older 
adults.70 Although not diagnostic, these EEG findings may help shed light on the cognitive 
deficits often reported by individuals with late-life depression. 
PSYCHOTHERAPIES 
Several evidence-based psychotherapies have been shown to be effective in the treatment of 
late-life depression, even in those with associated cognitive impairments. Psychotherapy should 
always be considered for individuals with MCI and early AD, especially, as older adults typically 
only show an adequate response in approximately 30% after a trial of a first-line antidepressant.71 
Cognitive Behavioral Therapy 
Cognitive-behavioral therapy (CBT) has become one of the more common treatments for a 
wide-range of disorders, including depression, posttraumatic stress disorder, anxiety, insomnia, 
and so forth. It is based on the assumption that maladaptive patterns of thought and behavior 
contribute to the development of emotional distress, such as depression. CBT focuses on breaking 
the links between dysfunctional cognitions, emotions, and behaviors. One recent meta-analysis72 
found that CBT and problem-solving therapy (PST) were more effective than other therapies in 
treating late-life depression. Furthermore, research has shown CBT to be effective even when 
applied to individuals with MCI.73 
Interpersonal Therapy 
Interpersonal therapy (IPT) concludes that the development of depressive symptoms is 
influenced by the relationships between patients and their significant others. For treatment, it 
combines techniques from supportive and psychodynamic therapies, focusing on interactions 
between the therapists and the patients, with the goal of generalizing positive interactions toward 
the patients’ significant others. IPT has been shown to be effective in the treatment of treatment-
resistant depression for younger to middle-aged adults,74 although there are fewer studies in older 
adults. One study75 showed that IPT, when modified to include patients’ caregivers, was effective 
in reducing depressive symptoms in cognitively impaired individuals. 
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Problem-Solving Therapy 
PST focuses treatment on everyday problems, with the goal of improving coping skills to 
prevent distress. The therapists work with the patients to identify problems, develop a set of 
possible solutions, decide on one of these solutions, and then implement the solution (assessing 
its success). Two meta-analyses76,77 have shown that PST effectively treats late-life depression. 
Furthermore, these findings are supported by another meta-analysis indicating PST was more 
effective than several other psychotherapies.72 In a multisite clinical trial of older adults with 
depression and executive dysfunction, problem-solving was shown to be more effective than 
supportive therapy in reducing depressive symptoms (persisting long after the 12 weeks of 
treatment).78 Furthermore, late-life depression seems responsive to modified PSTs, including 
primary care–based PST, problem adaptation therapy, and home-bound PST for individual with 
cognitive impairments.79–81 
Reminiscence and Life Review 
Based on Erikson’s last stage of life span development focused on “meaning making,” 
reminiscence and life review therapies were designed to treat psychological disorders in older 
adults. The life review is a systematic process structured around life themes, such as one’s 
childhood, parenthood, work productivity, and so forth. For treatment, the therapists work with 
the patients to recall memories with the goal of focusing on positive life events and enhancing 
well-being. The life review process then focuses on developing a narrative of the person’s life, 
evaluating events and reframing and integrating them. There are 3 meta-analyses that have shown 
reminiscence and life review therapies to be effective in treating late-life depression72,82,83; 
however, these data were complicated by the variations in how these therapies are applied. 
HOLISTIC AND OTHER NONTRADITIONAL 
APPROACHES 
Because of a variety of reasons, for many older adults, holistic and other nontraditional 
approaches for treatment of depression may be more acceptable than psychopharmacologic and 
psychotherapeutic approaches. First, as nontraditional treatments (eg, physical activity, art 
therapy, meditation, and so forth) have been used by many for non–mental health reasons, older 
adults may be more open to their use, especially if they have no history of psychiatric treatment. 
Second, older adults may find it easier to speak with their physicians about their physical 
symptoms than their emotional or cognitive complaints. Therefore, offering holistic and 
nontraditional treatments, which may benefit both physical and mental health, may be more 
acceptable. Third, as the mental health community has grown in the integration and study of 
nontraditional treatments, the authors have found that, although not easy to study, these 
approaches may offer unique benefits for the treatment of late-life depression.84 
Physical Activity and Cognitive Training 
Physical exercise has been shown to have a significant impact on both late-life depression and 
cognition. A systematic review by Mura and Carta85 showed that most of the included studies 
showed reductions in depressive symptoms (with no other interventions used). Multiple studies 
have shown that exercise alone is equally effective, if not a powerful addition, to antidepressant 
medications.86–88 Moreover, exercise has the potential to improve cognitive functioning in older 
adults as well. Particularly, executive functions, for example, planning, working memory, 
problem-solving, and so forth, seem to have robust benefits from aerobic exercise.89 
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There also seems to be some evidence that cognitive training may have some cognitive 
benefits in depressed older adults.90,91 However, further research needs to be done to examine 
generalization from these effects to daily functioning. 
Technological Interventions 
Recent advances have allowed technological approaches to be combined with traditional 
treatments of mental health issues. Internet-based psychotherapies92 and exergaming93 can 
function independently or be further augmented with the use of mobile applications.94 However, 
there is not yet compelling evidence for the effectiveness of these approaches with older adults. 
Religion and Spirituality 
With the increased importance of cultural competency in mental health research, the role of 
religious and spirituality practices has gained recognition for the treatment of late-life depression. 
For example, studies on the use of yoga and meditation have shown significant reductions in 
depressive symptoms in older adults.95,96 However, the effects these practices have on cognition 
are not yet well known. Finally, research on the use of tai chi with older adults suggests 
improvements in depressive symptoms, physical functioning, and cognitive functioning as well as 
reductions in inflammatory C-reactive protein.97,98 
Music, Art, and Dance Therapy 
Various art therapies have been shown to have positive effects on both mood and cognition. 
Specifically, music therapy may improve depression and cognitive symptoms in older adults99,100 
and dance therapy has shown a significant effect on mood.101,102 
Ketamine 
Recent literature has indicated that ketamine, typically used as an intravenous anesthetic, has 
been shown to have rapid antidepressant efficacy in individuals with refractory major depressive 
disorder (MDD).103 Moreover, initial studies have not shown there to be lasting neurocognitive 
deficits secondary to ketamine treatment 1 week after administration, although there is an initial 
slowing in processing speed.104 
PHARMACOLOGIC APPROACHES 
Antidepressants 
Most of the recent literature on depression and cognition has focused on selective serotonin 
reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs). 
The results on SSRIs have been variable, depending largely on the medication being studied. 
Specifically, sertraline was indicated to improve episodic memory and executive functions,9 
whereas citalopram was shown to cause difficulties in response inhibition, verbal learning, and 
processing speed.105,106 Alternatively, there seems to be more compelling evidence of cognitive 
benefits from SNRIs.107,108 Alternatively, antidepressants with anticholinergic effects (ie, many 
tricyclic antidepressants) likely have detrimental effects on cognition.109 
Cholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists 
Research on the use of cholinesterase inhibitors for late-life depression and comorbid MCI are 
limited, with conflicting findings in terms of cognitive and mood outcomes. Interestingly, 
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research on donepezil has shown varying results, from positive effects on depression110,111 to no 
positive effects.112 Memantine, an N-methyl-D-aspartate antagonist, has not been shown to have 
any efficacy as a treatment of comorbid MDD.113–115 
BRAIN STIMULATION THERAPIES 
Electroconvulsive Therapy 
Although initially developed for the treatment of psychotic symptoms, ECT has been shown to 
be effective in the treatment of severe, treatment-resistant depression.116 Although not fully 
understood, ECT is thought to release multiple neurotransmitters, including glutamate, 
noradrenalin, dopamine, and serotonin.117,118 However, post-ECT cognitive adverse effects have 
been found. These effects tend to be time limited and include disorientation after each ECT 
session and both anterograde and retrograde amnesia, which can persist for 1 to 6 months after 
the last session.117,119 More subtle cognitive deficits have also been shown to be time limited and 
include decreases in processing speed, working memory, learning and memory, and executive 
functions.120,121 
Other Brain-Stimulation Therapies 
Rather than using an electrical current, transcranial magnetic stimulation (TMS) uses an 
electromagnet to stimulate brain regions. In one study, patients receiving repetitive TMS showed 
improvement in depressive symptoms, functioning, and cognitive performances.122–124 Although 
not yet used to study late-life depression with comorbid depression, this intervention seems to be 
a promising area of future research. 
Although deep brain stimulation (DBS) has been shown to be associated with successful 
outcomes for treatment-resistant depression, responses differ among studies, with 6-month 
success rates ranging from 41% to 66%.125–128 Several DBS targets have been studied, including 
the subgenual cingulate region, subcallosal tracts, nucleus accumbens, ventral striatum, inferior 
thalamic peduncle, and habenula. At this time, there is not compelling evidence for cognitive 
benefits of DBS for patients with late-life depression and comorbid cognitive impairment. 
SUMMARY 
Although the understanding of the relationship between depression and cognition has grown 
significantly over the past several years, researchers continue to uncover more details regarding 
the complex interplay between these two factors. There have been several promising 
developments recently, especially with advances in neuroimaging and biomarker research. 
Additionally, although several therapeutic modalities have been researched for the treatment of 
late-life depression, many of them have been limited by factors, including providers’ experience 
and/or treatment availability. Given the current literature, optimal assessment and treatment of 
older adults with depression should include multiple modalities, such as neuroimaging, 
genotyping, and risk factor burden calculations, to better understand the patients’ prognosis and 
potential treatment response. Future research should then focus on more individualized 
treatments, pharmacologic and psychotherapeutic, for late-life depression in order to more 
effectively treat both cognitive and affective symptoms. 
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